Straight from the Investment for Advanced Therapies hosted by CMS Cameron-McKenna on Wednesday 3rd May, we sat down with Stéphane Boissel, CEO of TxCEll, to find out more about the unique development of their cellular immunotherapies using regulatory T Cells to treat severe inflammatory and autoimmune disease. In this video interview, Stéphane also explains why their CAR Treg platform offers such a rare investment opportunity. Finally, we asked Stéphane what the difficulties and opportunities are in bringing advanced therapies to patients.
WATCH THE EXCLUSIVE INTERVIEW WITH STEPHANE BOISSEL, CEO OF TXCELL
Investment for Advanced Therapies took place on Wednesday 3rd May and was be the C-Level meeting place for heavyweight investors, analysts, biotechs, venture partners and industry experts who are driving the industry forward.
TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need. TxCell targets a wide range of inflammatory diseases (both T-cell and B-cell-mediated) including Crohn’s disease, lupus nephritis, bullous pemphigoid and multiple sclerosis, as well as transplantation-related inflammatory disorders. www.txcell.com